Strategic partnerships CellMosaic specializes in site-specific and single-label conjugation with a strong custom conjugation service legacy and a growing product line. This positions them well for collaborations with pharma and biotech firms seeking in-house conjugation capabilities or specialized reagents, enabling co-developed kits and joint offerings.

In-house kits expansion Recent launches of PerKit based ADC and PDC kits and the June 2026 line of antibody and protein labeling kits indicate a push to monetize their conjugation technologies through readily consumable products. Target customers include research labs and CROs aiming to replicate high-quality conjugations in-house.

AqT and platform leverage AqT linker technologies and related crosslinking reagents underpin a scalable platform for drug conjugates and delivery. This creates upsell opportunities with customers needing robust conjugation chemistries, enabling pilot collaborations, pilot-scale kits, and bespoke reagent packages.

Clinical and diagnostic potential New maleimide-activated protein carriers and antibody-drug conjugate related products expand applicability to immunization, diagnostics, and therapeutic development. Sales discussions can target pharmaceutical developers and diagnostic companies seeking validated conjugation tools and ready-to-use components.

Strategic collaborations Past partnerships and ongoing product developments like integration with mass spectrometry capabilities and research tools suggest opportunities for co-marketing, white-label kits, and joint technology licensing with adjacent suppliers and contract research organizations.